<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583138</url>
  </required_header>
  <id_info>
    <org_study_id>1011007631b</org_study_id>
    <secondary_id>R01DA030768</secondary_id>
    <nct_id>NCT03583138</nct_id>
  </id_info>
  <brief_title>HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)</brief_title>
  <official_title>Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are
      dependent on opioids. This study is funded by the National Institute on Drug Abuse
      (R01DA030768, Altice, PI; Taxman &amp; Lawson, Co-PIs) and is being conducted by George Mason
      University, Yale University, and Howard University.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide
      resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to
      examine if there are differences in HIV, drug use, and other outcomes between individuals
      receiving treatment versus individuals actively using, not actively using and not in
      treatment, and individuals on Methadone, Suboxone, or in some other treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2014</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VL &lt;400</measure>
    <time_frame>Month 0</time_frame>
    <description>Blood test for HIV viral load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ cell count</measure>
    <time_frame>Month 0</time_frame>
    <description>Blood test for HIV CD4+ cell count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VL &lt;400</measure>
    <time_frame>6 months</time_frame>
    <description>Blood test for HIV viral load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ cell count</measure>
    <time_frame>6 months</time_frame>
    <description>Blood test for HIV CD4+ cell count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VL &lt;400</measure>
    <time_frame>12 months</time_frame>
    <description>Blood test for HIV viral load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ cell count</measure>
    <time_frame>12 months</time_frame>
    <description>Blood test for HIV CD4+ cell count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV risk behaviors</measure>
    <time_frame>Month 0</time_frame>
    <description>Survey for HIV risks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV risk behaviors</measure>
    <time_frame>6 months</time_frame>
    <description>Survey for HIV risks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV risk behaviors</measure>
    <time_frame>12 months</time_frame>
    <description>Survey for HIV risks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in HIV care</measure>
    <time_frame>Month 0</time_frame>
    <description>Survey data for retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in HIV care</measure>
    <time_frame>6 months</time_frame>
    <description>Survey data for retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in HIV care</measure>
    <time_frame>12 months</time_frame>
    <description>Survey data for retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use</measure>
    <time_frame>Month 0</time_frame>
    <description>Measure of relapse to opioid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of relapse to opioid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of relapse to opioid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically assisted therapy retention</measure>
    <time_frame>Month 0</time_frame>
    <description>Measure of length of time on Methadone or Buprenorphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically assisted therapy retention</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of length of time on Methadone or Buprenorphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically assisted therapy retention</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of length of time on Methadone or Buprenorphine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reincarceration</measure>
    <time_frame>Month 0</time_frame>
    <description>Measure of rearrest and reincarceration</description>
  </other_outcome>
  <other_outcome>
    <measure>Reincarceration</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of rearrest and reincarceration</description>
  </other_outcome>
  <other_outcome>
    <measure>Reincarceration</measure>
    <time_frame>12 months</time_frame>
    <description>Measure of rearrest and reincarceration</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">159</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Opiate Addiction</condition>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <description>Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No buprenorphine</arm_group_label>
    <description>No buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <description>To provide buprenorphine for 12 months for those who are interested in receiving it.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health
        insurance accepted at Lab Corp, are able to read and understand English, and live in
        Washington, DC and plan to remain in DC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV+, confirmed by rapid HIV test

          2. Meet DSM-IV criteria for opioid dependence

          3. 18 years or older

          4. Have health insurance that is accepted at Lab Corp.

        Exclusion Criteria:

          1. Are &lt;18 years old;

          2. Are HIV negative;

          3. Are Unable to communicate in English;

          4. Are not able to provide informed consent;

          5. Do not meet DSM-IV criteria for opioid dependence;

          6. Plan to leave the DC area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrick Altice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine/AIDS Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faye Taxman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Mason University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Lawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Opiate Addiction</keyword>
  <keyword>Drug Dependence</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

